Novo Integrated Sciences, Inc. (NVOS)
USD 0.0
(15.38%)
USD 0.0
(15.38%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.5 Million USD | -6.11% |
| 2022 | 14.38 Million USD | 77.66% |
| 2021 | 8.09 Million USD | 11.05% |
| 2020 | 7.29 Million USD | 79.6% |
| 2019 | 4.05 Million USD | -18.68% |
| 2018 | 4.99 Million USD | 61.55% |
| 2017 | 3.09 Million USD | 1774.24% |
| 2016 | 164.88 Thousand USD | -58.94% |
| 2015 | 401.57 Thousand USD | 19.7% |
| 2014 | 335.47 Thousand USD | -25.11% |
| 2013 | 447.98 Thousand USD | -45.27% |
| 2012 | 818.53 Thousand USD | -63.2% |
| 2011 | 2.22 Million USD | -4.53% |
| 2010 | 2.32 Million USD | 2038.19% |
| 2009 | 108.95 Thousand USD | -19.94% |
| 2008 | 136.08 Thousand USD | -94.52% |
| 2007 | 2.48 Million USD | 69.91% |
| 2006 | 1.46 Million USD | 37.02% |
| 2005 | 1.06 Million USD | 355.39% |
| 2004 | 234.44 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 3.41 Million USD | 19.32% |
| 2024 Q1 | 5.26 Million USD | 30.82% |
| 2024 Q2 | 2.86 Million USD | -45.57% |
| 2023 Q1 | 3.98 Million USD | -17.17% |
| 2023 Q4 | 4.02 Million USD | 46.55% |
| 2023 FY | 13.5 Million USD | -6.11% |
| 2023 Q3 | 2.74 Million USD | -0.48% |
| 2023 Q2 | 2.75 Million USD | -30.74% |
| 2022 FY | 14.38 Million USD | 77.66% |
| 2022 Q1 | 2.63 Million USD | -4.99% |
| 2022 Q4 | 4.8 Million USD | 33.09% |
| 2022 Q3 | 3.61 Million USD | 8.23% |
| 2022 Q2 | 3.33 Million USD | 26.88% |
| 2021 Q1 | 1.56 Million USD | -66.95% |
| 2021 Q3 | 1.68 Million USD | -19.01% |
| 2021 Q4 | 2.76 Million USD | 64.53% |
| 2021 FY | 8.09 Million USD | 11.05% |
| 2021 Q2 | 2.07 Million USD | 32.39% |
| 2020 FY | 7.29 Million USD | 79.6% |
| 2020 Q1 | 992.49 Thousand USD | -1.41% |
| 2020 Q2 | 993.77 Thousand USD | 0.13% |
| 2020 Q3 | 556.8 Thousand USD | -43.97% |
| 2020 Q4 | 4.74 Million USD | 752.76% |
| 2019 Q1 | 1.09 Million USD | 18.54% |
| 2019 FY | 4.05 Million USD | -18.68% |
| 2019 Q4 | 1 Million USD | 1.09% |
| 2019 Q2 | 958.35 Thousand USD | -12.79% |
| 2019 Q3 | 995.83 Thousand USD | 3.91% |
| 2018 FY | 4.99 Million USD | 61.55% |
| 2018 Q4 | 927.01 Thousand USD | -14.32% |
| 2018 Q3 | 1.08 Million USD | -44.94% |
| 2018 Q2 | 1.96 Million USD | 92.95% |
| 2018 Q1 | 1.01 Million USD | 9.79% |
| 2017 FY | 3.09 Million USD | 1774.24% |
| 2017 Q4 | 927.64 Thousand USD | -4.75% |
| 2017 Q3 | 973.93 Thousand USD | 2530.61% |
| 2017 Q2 | 37.02 Thousand USD | -12.83% |
| 2017 Q1 | 42.47 Thousand USD | 13.86% |
| 2016 FY | 164.88 Thousand USD | -58.94% |
| 2016 Q4 | 37.3 Thousand USD | 118.78% |
| 2016 Q1 | -47.42 Thousand USD | -200.37% |
| 2016 Q2 | 68.06 Thousand USD | 243.51% |
| 2016 Q3 | 17.05 Thousand USD | -74.95% |
| 2015 Q2 | 45.42 Thousand USD | -51.66% |
| 2015 Q4 | 47.25 Thousand USD | -86.74% |
| 2015 FY | 401.57 Thousand USD | 19.7% |
| 2015 Q3 | 356.31 Thousand USD | 684.36% |
| 2015 Q1 | 93.97 Thousand USD | 32.99% |
| 2014 Q3 | 182.13 Thousand USD | 279.05% |
| 2014 FY | 335.47 Thousand USD | -25.11% |
| 2014 Q1 | 76.96 Thousand USD | -25.28% |
| 2014 Q2 | 48.05 Thousand USD | -37.57% |
| 2014 Q4 | 70.66 Thousand USD | -61.2% |
| 2013 FY | 447.98 Thousand USD | -45.27% |
| 2013 Q1 | -108.53 Thousand USD | -164.56% |
| 2013 Q2 | 100.9 Thousand USD | 192.97% |
| 2013 Q4 | 102.99 Thousand USD | -38.31% |
| 2013 Q3 | 166.94 Thousand USD | 65.45% |
| 2012 Q4 | 168.11 Thousand USD | -52.65% |
| 2012 Q3 | 355.07 Thousand USD | -11.65% |
| 2012 FY | 818.53 Thousand USD | -63.2% |
| 2012 Q1 | 410.25 Thousand USD | -18.18% |
| 2012 Q2 | 401.87 Thousand USD | -2.04% |
| 2011 FY | 2.22 Million USD | -4.53% |
| 2011 Q3 | 481.15 Thousand USD | -42.13% |
| 2011 Q4 | 501.4 Thousand USD | 4.21% |
| 2011 Q1 | -1.69 Million USD | -2180.27% |
| 2011 Q2 | 831.4 Thousand USD | 148.98% |
| 2010 Q1 | -1.08 Million USD | -286.53% |
| 2010 Q4 | 81.59 Thousand USD | -93.03% |
| 2010 Q2 | 654.41 Thousand USD | 160.28% |
| 2010 Q3 | 1.16 Million USD | 78.78% |
| 2010 FY | 2.32 Million USD | 2038.19% |
| 2009 Q3 | 319.43 Thousand USD | 8.97% |
| 2009 FY | 108.95 Thousand USD | -19.94% |
| 2009 Q4 | 582.03 Thousand USD | 82.21% |
| 2009 Q2 | 293.13 Thousand USD | -13.42% |
| 2009 Q1 | 338.57 Thousand USD | 25.78% |
| 2008 Q1 | 852.99 Thousand USD | 75.24% |
| 2008 Q4 | 269.18 Thousand USD | 51.6% |
| 2008 FY | 136.08 Thousand USD | -94.52% |
| 2008 Q2 | 178.12 Thousand USD | -79.12% |
| 2008 Q3 | 177.56 Thousand USD | -0.32% |
| 2007 Q4 | 486.74 Thousand USD | 3.3% |
| 2007 Q1 | 517.26 Thousand USD | -7.77% |
| 2007 Q3 | 471.18 Thousand USD | -30.16% |
| 2007 FY | 2.48 Million USD | 69.91% |
| 2007 Q2 | 674.67 Thousand USD | 30.43% |
| 2006 FY | 1.46 Million USD | 37.02% |
| 2006 Q3 | 259.37 Thousand USD | 106.76% |
| 2006 Q1 | 278.11 Thousand USD | 132.09% |
| 2006 Q2 | 125.44 Thousand USD | -54.9% |
| 2006 Q4 | 560.81 Thousand USD | 116.22% |
| 2005 FY | 1.06 Million USD | 355.39% |
| 2005 Q2 | 236.58 Thousand USD | 0.0% |
| 2005 Q4 | 119.83 Thousand USD | -72.33% |
| 2005 Q3 | 433.11 Thousand USD | 83.07% |
| 2004 FY | 234.44 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acadia Healthcare Company, Inc. | 176.01 Million USD | 92.327% |
| Addus HomeCare Corporation | 248.92 Million USD | 94.574% |
| AirSculpt Technologies, Inc. | 118.32 Million USD | 88.585% |
| Amedisys, Inc. | 834.47 Million USD | 98.382% |
| American Oncology Network, Inc. | 83.97 Million USD | 83.917% |
| Astrana Health, Inc. | 112.59 Million USD | 88.005% |
| Aveanna Healthcare Holdings Inc. | 587.36 Million USD | 97.701% |
| IMAC Holdings, Inc. | 5.02 Million USD | -168.66% |
| biote Corp. | 98.82 Million USD | 86.334% |
| Cryo-Cell International, Inc. | 35.2 Million USD | 61.637% |
| Cross Country Healthcare, Inc. | 337.69 Million USD | 96.001% |
| COMPASS Pathways plc | 136.91 Million USD | 90.136% |
| DocGo Inc. | 180.32 Million USD | 92.51% |
| The Ensign Group, Inc. | 335.39 Million USD | 95.973% |
| Healthcare Services Group, Inc. | 189.09 Million USD | 92.858% |
| InnovAge Holding Corp. | 558.25 Million USD | 97.581% |
| Assure Holdings Corp. | 15.43 Million USD | 12.521% |
| The Joint Corp. | 109.22 Million USD | 87.635% |
| LifeStance Health Group, Inc. | 491.23 Million USD | 97.251% |
| Mobile-health Network Solutions Class A Ordinary Shares | 18.24 Million USD | 25.963% |
| ModivCare Inc. | 586.89 Million USD | 97.699% |
| NewGenIvf Group Limited | 1.63 Million USD | -723.759% |
| Option Care Health, Inc. | 666.62 Million USD | 97.974% |
| P3 Health Partners Inc. | 199.56 Million USD | 93.232% |
| P3 Health Partners Inc. | 199.56 Million USD | 93.232% |
| The Pennant Group, Inc. | 88.99 Million USD | 84.824% |
| Surgery Partners, Inc. | 319.5 Million USD | 95.773% |
| Syra Health Corp. Class A Common Stock | 4.29 Million USD | -214.127% |
| Talkspace, Inc. | 97.58 Million USD | 86.16% |
| Talkspace, Inc. | 97.58 Million USD | 86.16% |
| The Oncology Institute, Inc. | 136.59 Million USD | 90.112% |
| The Oncology Institute, Inc. | 136.59 Million USD | 90.112% |